{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:49:23Z","timestamp":1791492563549,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"DOI":"10.1038\/s41433-026-04918-y","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:18:18Z","timestamp":1791443898000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-treatment residual masses in orbital lymphoma: incidence, risk factors, and prognostic impact"],"prefix":"10.1038","author":[{"given":"Yeong A","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Kyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3043-7222","authenticated-orcid":false,"given":"Ho-Seok","family":"Sa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"4918_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ophtha.2017.05.037","volume":"125","author":"MT Yen","year":"2018","unstructured":"Yen MT, Bilyk JR, Wladis EJ, Bradley EA, Mawn LA. Treatments for ocular adnexal lymphoma: a Report by the American Academy of Ophthalmology. Ophthalmology. 2018;125:127\u201336.","journal-title":"Ophthalmology"},{"key":"4918_CR2","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/S0360-3016(03)00767-3","volume":"57","author":"CY Fung","year":"2003","unstructured":"Fung CY, Tarbell NJ, Lucarelli MJ, Goldberg SI, Linggood RM, Harris NL, et al. Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes. Int J Radiat Oncol Biol Phys. 2003;57:1382\u201391.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4918_CR3","doi-asserted-by":"crossref","unstructured":"Savino G, Midena G, Blasi MA, Battendieri R, Grimaldi G, Maceroni M, et al. Orbital and eyelid B-cell lymphoma: a multicenter retrospective study. Cancers (Basel). 2020;2\u201312.","DOI":"10.3390\/cancers12092538"},{"key":"4918_CR4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/01.pas.0000213350.49767.46","volume":"31","author":"JA Ferry","year":"2007","unstructured":"Ferry JA, Fung CY, Zukerberg L, Lucarelli MJ, Hasserjian RP, Preffer FI, et al. Lymphoma of the ocular adnexa: a study of 353 cases. Am J Surg Pathol. 2007;31:170\u201384.","journal-title":"Am J Surg Pathol"},{"key":"4918_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/j.semdp.2015.10.004","volume":"33","author":"K Mulay","year":"2016","unstructured":"Mulay K, Honavar SG. An update on ocular adnexal lymphoma. Semin Diagn Pathol. 2016;33:164\u201372.","journal-title":"Semin Diagn Pathol"},{"key":"4918_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/00000441-200602000-00013","volume":"331","author":"S Ahmed","year":"2006","unstructured":"Ahmed S, Shahid RK, Sison CP, Fuchs A, Mehrotra B. Orbital lymphomas: a clinicopathologic study of a rare disease. Am J Med Sci. 2006;331:79\u201383.","journal-title":"Am J Med Sci"},{"key":"4918_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"4918_CR8","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/cam4.2798","volume":"9","author":"S Tokola","year":"2020","unstructured":"Tokola S, Kuitunen H, Turpeenniemi-Hujanen T, Kuittinen O. Significance of bulky mass and residual tumour-treated with or without consolidative radiotherapy-To the risk of relapse in DLBCL patients. Cancer Med. 2020;9:1966\u201377.","journal-title":"Cancer Med"},{"key":"4918_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.clml.2017.12.002","volume":"18","author":"\u00d8 Fluge","year":"2018","unstructured":"Fluge \u00d8, Manns\u00e5ker B, Torp A, Mjaaland I, Helgeland L, Klos J, et al. Consolidative radiotherapy to residual masses after chemotherapy is associated with improved outcome in diffuse large B-cell lymphoma. a retrospective, population-based study. Clin Lymphoma Myeloma Leuk. 2018;18:125\u201335.e3.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4918_CR10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/028418600750013393","volume":"39","author":"M Rodriguez-Catarino","year":"2000","unstructured":"Rodriguez-Catarino M, Jerkeman M, Ahlstr\u00f6m H, Glimelius B, Hagberg H. Residual mass in aggressive lymphoma-does size, measured by computed tomography, influence clinical outcome? Acta Oncol. 2000;39:485\u20139.","journal-title":"Acta Oncol"},{"key":"4918_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1385\/MO:22:4:383","volume":"22","author":"A Avil\u00e9s","year":"2005","unstructured":"Avil\u00e9s A, Neri N, Delgado S, P\u00e9rez F, Nambo MJ, Cleto S, et al. Residual disease after chemotherapy in aggressive malignant lymphoma: the role of radiotherapy. Med Oncol. 2005;22:383\u20137.","journal-title":"Med Oncol"},{"key":"4918_CR12","doi-asserted-by":"crossref","unstructured":"Shi J, Zhu T, Zhou M, Zhou X, Song X, Wang Y, et al. Predicting the risk of distant and local recurrence for patients with ocular adnexal extranodal marginal zone lymphoma: a matched case\u2013control study. Br J Ophthalmol. 2022:bjophthalmol-2022-321656.","DOI":"10.1136\/bjo-2022-321656"},{"key":"4918_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ajo.2018.11.002","volume":"199","author":"TG Olsen","year":"2019","unstructured":"Olsen TG, Holm F, Mikkelsen LH, Rasmussen PK, Coupland SE, Esmaeli B, et al. Orbital lymphoma-an international multicenter retrospective study. Am J Ophthalmol. 2019;199:44\u201357.","journal-title":"Am J Ophthalmol"},{"key":"4918_CR14","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1136\/bjophthalmol-2020-315875","volume":"105","author":"M Kwon","year":"2021","unstructured":"Kwon M, Lee JS, Lee C, Yoon DH, Sa HS. Prognostic factors for relapse and survival among patients with ocular adnexal lymphoma: validation of the eighth edition of the American Joint Committee on Cancer (AJCC) TNM classification. Br J Ophthalmol. 2021;105:279\u201384.","journal-title":"Br J Ophthalmol"},{"key":"4918_CR15","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36:1720\u201348.","journal-title":"Leukemia"},{"key":"4918_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.eclinm.2018.10.001","volume":"4-5","author":"YW Jeon","year":"2018","unstructured":"Jeon YW, Yang HJ, Choi BO, Jung SE, Park KS, O JH, et al. Comparison of selection and long-term clinical outcomes between chemotherapy and radiotherapy as primary therapeutic modality for ocular adnexal MALT lymphoma. EClinicalMedicine. 2018;4-5:32\u201342.","journal-title":"EClinicalMedicine"},{"key":"4918_CR17","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1200\/JCO.1988.6.6.931","volume":"6","author":"GP Canellos","year":"1988","unstructured":"Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol. 1988;6:931\u20133.","journal-title":"J Clin Oncol"},{"key":"4918_CR18","first-page":"724","volume":"27","author":"TP Oktariana","year":"2022","unstructured":"Oktariana TP, Andriana A, Nugroho RS. The outcome of radiation therapy as a primary treatment in orbital lymphoma: a systematic review. Rep Pract Oncol Radiother. 2022;27:724\u201333.","journal-title":"Rep Pract Oncol Radiother"},{"key":"4918_CR19","doi-asserted-by":"crossref","unstructured":"Choi S, Seo M, Park SH, Jo JC, Chae SW, Lee JH, et al. Clinicopathologic characteristics associated with prognosis in ocular extranodal marginal zone B cell lymphoma. Medicina (Kaunas). 2022;58\u201381.","DOI":"10.3390\/medicina58060818"},{"key":"4918_CR20","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/sj.eye.6700379","volume":"17","author":"C Jenkins","year":"2003","unstructured":"Jenkins C, Rose GE, Bunce C, Cree I, Norton A, Plowman PN, et al. Clinical features associated with survival of patients with lymphoma of the ocular adnexa. Eye (Lond). 2003;17:809\u201320.","journal-title":"Eye (Lond)"},{"key":"4918_CR21","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1200\/JCO.1988.6.12.1832","volume":"6","author":"A Surbone","year":"1988","unstructured":"Surbone A, Longo DL, DeVita VT Jr., Ihde DC, Duffey PL, Jaffe ES, et al. Residual abdominal masses in aggressive non-Hodgkin\u2019s lymphoma after combination chemotherapy: significance and management. J Clin Oncol. 1988;6:1832\u20137.","journal-title":"J Clin Oncol"},{"key":"4918_CR22","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.surg.2018.05.039","volume":"164","author":"L Kane","year":"2018","unstructured":"Kane L, Savas H, DeCamp MM, Bharat A. Utility of minimally invasive thoracoscopy for assessment of residual mediastinal lymphoma. Surgery. 2018;164:825\u201330.","journal-title":"Surgery"},{"key":"4918_CR23","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6413553","volume":"2022","author":"Y Xu","year":"2022","unstructured":"Xu Y, Cheng L, Yuan L, Yi Q, Xiao L, Chen H. Progress on brain and ocular lymphatic system. Biomed Res Int. 2022;2022:6413553.","journal-title":"Biomed Res Int"},{"key":"4918_CR24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0360-3016(01)01626-1","volume":"51","author":"T Girinsky","year":"2001","unstructured":"Girinsky T, Guillot-Vals D, Koscielny S, Cosset JM, Ganem G, Carde P, et al. A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment. Int J Radiat Oncol Biol Phys. 2001;51:148\u201355.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4918_CR25","doi-asserted-by":"publisher","first-page":"e659","DOI":"10.1016\/j.ijrobp.2011.03.050","volume":"81","author":"JS Goda","year":"2011","unstructured":"Goda JS, Le LW, Lapperriere NJ, Millar BA, Payne D, Gospodarowicz MK, et al. Localized orbital mucosa-associated lymphoma tissue lymphoma managed with primary radiation therapy: efficacy and toxicity. Int J Radiat Oncol Biol Phys. 2011;81:e659\u201366.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4918_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ijrobp.2015.01.025","volume":"92","author":"N Jegadeesh","year":"2015","unstructured":"Jegadeesh N, Rajpara R, Esiashvili N, Shi Z, Liu Y, Okwan-Duodu D, et al. Predictors of local recurrence after rituximab-based chemotherapy alone in stage III and IV diffuse large B-cell lymphoma: guiding decisions for consolidative radiation. Int J Radiat Oncol Biol Phys. 2015;92:107\u201312.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4918_CR27","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.3390\/cancers13163952","volume":"13","author":"A Gallamini","year":"2021","unstructured":"Gallamini A, Kurlapski M, Zaucha JM. FDG-PET\/CT for the management of post-chemotherapy residual mass in Hodgkin lymphoma. Cancers. 2021;13:3952.","journal-title":"Cancers"},{"key":"4918_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/bjh.13420","volume":"170","author":"HJ Adams","year":"2015","unstructured":"Adams HJ, Nievelstein RA, Kwee TC. Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis. Br J Haematol. 2015;170:185\u201391.","journal-title":"Br J Haematol"},{"key":"4918_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/annonc\/11.suppl_1.S147","volume":"11","author":"NG Mikhaeel","year":"2000","unstructured":"Mikhaeel NG, Timothy AR, Hain SF, O\u2019Doherty MJ. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol. 2000;11:147\u201350.","journal-title":"Ann Oncol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04918-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04918-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04918-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:02:28Z","timestamp":1791489748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04918-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":29,"alternative-id":["4918"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04918-y","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"We retrospectively reviewed all consecutive individuals with biopsy-confirmed primary OL who were treated by a senior author (HSS) between March 2011 and December 2023. Individuals were excluded if they had conjunctival lymphoma, secondary OL, or a follow-up period of less than six months after treatment. In accordance with the Declaration of Helsinki, the study was approved by the institutional review board of Asan Medical Centre (IRB No. 2023-0082), and all participants provided written informed consent.","order":2,"name":"Ethics","label":"Study design and ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}